BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kachalaki S, Ebrahimi M, Mohamed Khosroshahi L, Mohammadinejad S, Baradaran B. Cancer chemoresistance; biochemical and molecular aspects: a brief overview. Eur J Pharm Sci 2016;89:20-30. [PMID: 27094906 DOI: 10.1016/j.ejps.2016.03.025] [Cited by in Crossref: 80] [Cited by in F6Publishing: 87] [Article Influence: 13.3] [Reference Citation Analysis]
Number Citing Articles
1 Zhang J, Wang Y, Chen J, Liang X, Han H, Yang Y, Li Q, Wang Y. Inhibition of cell proliferation through an ATP-responsive co-delivery system of doxorubicin and Bcl-2 siRNA. Int J Nanomedicine 2017;12:4721-32. [PMID: 28740380 DOI: 10.2147/IJN.S135086] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
2 Pepper C, Tu H, Morrill P, Garcia-Rates S, Fegan C, Greenfield S. Tumor cell migration is inhibited by a novel therapeutic strategy antagonizing the alpha-7 receptor. Oncotarget 2017;8:11414-24. [PMID: 28077796 DOI: 10.18632/oncotarget.14545] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
3 Pass HI, Lavilla C, Canino C, Goparaju C, Preiss J, Noreen S, Blandino G, Cioce M. Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin. Oncotarget 2016;7:56408-21. [PMID: 27486763 DOI: 10.18632/oncotarget.10895] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
4 Nadysev GY, Tikhomirov AS, Lin M, Yang Y, Dezhenkova LG, Chen H, Kaluzhny DN, Schols D, Shtil AA, Shchekotikhin AE, Chueh PJ. Aminomethylation of heliomycin: Preparation and anticancer characterization of the first series of semi-synthetic derivatives. European Journal of Medicinal Chemistry 2018;143:1553-62. [DOI: 10.1016/j.ejmech.2017.10.055] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
5 Jovanović M, Dragoj M, Zhukovsky D, Dar'in D, Krasavin M, Pešić M, Podolski-Renić A. Novel TrxR1 Inhibitors Show Potential for Glioma Treatment by Suppressing the Invasion and Sensitizing Glioma Cells to Chemotherapy. Front Mol Biosci 2020;7:586146. [PMID: 33134322 DOI: 10.3389/fmolb.2020.586146] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
6 Tikhomirov AS, Lin C, Volodina YL, Dezhenkova LG, Tatarskiy VV, Schols D, Shtil AA, Kaur P, Chueh PJ, Shchekotikhin AE. New antitumor anthra[2,3-b]furan-3-carboxamides: Synthesis and structure-activity relationship. European Journal of Medicinal Chemistry 2018;148:128-39. [DOI: 10.1016/j.ejmech.2018.02.027] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
7 Lucianò AM, Perciballi E, Fiore M, Del Bufalo D, Tata AM. The Combination of the M2 Muscarinic Receptor Agonist and Chemotherapy Affects Drug Resistance in Neuroblastoma Cells. Int J Mol Sci 2020;21:E8433. [PMID: 33182656 DOI: 10.3390/ijms21228433] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Rashedi J, Ghorbani Haghjo A, Mesgari Abbasi M, Dastranj Tabrizi A, Yaqoubi S, Sanajou D, Ashrafi Jigheh Z, Namvaran A, Mohammadi A, Mohammadi Khoshraj J, Baradaran B. Anti-tumor Effect of Quercetin Loaded Chitosan Nanoparticles on Induced Colon Cancer in Wistar Rats. Adv Pharm Bull 2019;9:409-15. [PMID: 31592135 DOI: 10.15171/apb.2019.048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Guan S, Wei J, Huang L, Wu L. Chemotherapy and chemo-resistance in nasopharyngeal carcinoma. Eur J Med Chem 2020;207:112758. [PMID: 32858472 DOI: 10.1016/j.ejmech.2020.112758] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Pan J, Miao D, Chen L. Germacrone reverses adriamycin resistance in human chronic myelogenous leukemia K562/ADM cells by suppressing MDR1 gene/P-glycoprotein expression. Chem Biol Interact 2018;288:32-7. [PMID: 29655913 DOI: 10.1016/j.cbi.2018.04.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
11 Loo JF, Yang C, Tsang HL, Lau PM, Yong KT, Ho HP, Kong SK. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening. Analyst 2017;142:3579-87. [PMID: 28852760 DOI: 10.1039/c7an01026e] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
12 Sun T, Liu Y, Li M, Yu H, Piao H. Administration with hyperoside sensitizes breast cancer cells to paclitaxel by blocking the TLR4 signaling. Mol Cell Probes 2020;53:101602. [PMID: 32447047 DOI: 10.1016/j.mcp.2020.101602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Hu X, Wang J, Chai J, Yu X, Zhang Y, Feng Y, Qin J, Yu H. Chaetomugilin J Enhances Apoptosis in Human Ovarian Cancer A2780 Cells Induced by Cisplatin Through Inhibiting Pink1/Parkin Mediated Mitophagy. Onco Targets Ther 2020;13:9967-76. [PMID: 33116582 DOI: 10.2147/OTT.S273435] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Sanchez-Carranza JN, González-Maya L, Razo-Hernández RS, Salas-Vidal E, Nolasco-Quintana NY, Clemente-Soto AF, García-Arizmendi L, Sánchez-Ramos M, Marquina S, Alvarez L. Achillin Increases Chemosensitivity to Paclitaxel, Overcoming Resistance and Enhancing Apoptosis in Human Hepatocellular Carcinoma Cell Line Resistant to Paclitaxel (Hep3B/PTX). Pharmaceutics 2019;11:E512. [PMID: 31590262 DOI: 10.3390/pharmaceutics11100512] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
15 Jiang H, Ju H, Zhang L, Lu H, Jie K. microRNA-577 suppresses tumor growth and enhances chemosensitivity in colorectal cancer. J Biochem Mol Toxicol. 2017;31. [PMID: 28150434 DOI: 10.1002/jbt.21888] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
16 Zou W, Ma X, Yang H, Hua W, Chen B, Cai G. Hepatitis B X-interacting protein promotes cisplatin resistance and regulates CD147 via Sp1 in ovarian cancer. Exp Biol Med (Maywood) 2017;242:497-504. [PMID: 28056551 DOI: 10.1177/1535370216685007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
17 Dong X, Wang L, Han Z, Zhou L, Shan L, Ding Y, Xu W, Li J, Su Y, Cai R, Xiong G, Diao D, Dai M, Jia C, Zheng H. Different functions of DEPTOR in modulating sensitivity to chemotherapy for esophageal squamous cell carcinoma. Exp Cell Res 2017;353:35-45. [PMID: 28267437 DOI: 10.1016/j.yexcr.2017.03.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
18 Hua Z, Zhan Y, Zhang S, Dong Y, Jiang M, Tan F, Liu Z, Thiele CJ, Li Z. P53/PUMA are potential targets that mediate the protection of brain-derived neurotrophic factor (BDNF)/TrkB from etoposide-induced cell death in neuroblastoma (NB). Apoptosis 2018;23:408-19. [PMID: 29959561 DOI: 10.1007/s10495-018-1467-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
19 Heffeter P, Pape VFS, Enyedy ÉA, Keppler BK, Szakacs G, Kowol CR. Anticancer Thiosemicarbazones: Chemical Properties, Interaction with Iron Metabolism, and Resistance Development. Antioxid Redox Signal 2019;30:1062-82. [PMID: 29334758 DOI: 10.1089/ars.2017.7487] [Cited by in Crossref: 66] [Cited by in F6Publishing: 54] [Article Influence: 16.5] [Reference Citation Analysis]
20 Treshalina HM, Romanenko VI, Kaluzhny DN, Treshalin MI, Nikitin AA, Tikhomirov AS, Shchekotikhin AE. Development and pharmaceutical evaluation of the anticancer Anthrafuran/Cavitron complex, a prototypic parenteral drug formulation. European Journal of Pharmaceutical Sciences 2017;109:631-7. [DOI: 10.1016/j.ejps.2017.09.025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
21 Hou Z, Tong X, Peng Y, Zhang B, Yan M. Broad targeting of triptolide to resistance and sensitization for cancer therapy. Biomedicine & Pharmacotherapy 2018;104:771-80. [DOI: 10.1016/j.biopha.2018.05.088] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
22 Deng X, Lin N, Fu J, Xu L, Luo H, Jin Y, Liu Y, Sun L, Su J. The Nrf2/PGC1α Pathway Regulates Antioxidant and Proteasomal Activity to Alter Cisplatin Sensitivity in Ovarian Cancer. Oxid Med Cell Longev 2020;2020:4830418. [PMID: 33294122 DOI: 10.1155/2020/4830418] [Reference Citation Analysis]
23 Piorecka K, Kurjata J, Stanczyk M, Stanczyk WA. Synthetic routes to nanomaterials containing anthracyclines: noncovalent systems. Biomater Sci 2018;6:2552-65. [PMID: 30140825 DOI: 10.1039/c8bm00739j] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
24 Arnst KE, Banerjee S, Chen H, Deng S, Hwang DJ, Li W, Miller DD. Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy. Med Res Rev 2019;39:1398-426. [PMID: 30746734 DOI: 10.1002/med.21568] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 11.7] [Reference Citation Analysis]
25 Yang RM, Zhang XL, Wang L, Huang JP, Yang J, Yan YJ, Luo JY, Wang XT, Huang SX. α-Pyrone Derivatives from a Streptomyces Strain Resensitize Tamoxifen Resistance in Breast Cancer Cells. Nat Prod Bioprospect 2017;7:329-34. [PMID: 28634711 DOI: 10.1007/s13659-017-0136-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
26 Mohammed S, Harikumar KB. Role of Resveratrol in Chemosensitization of Cancer. Role of Nutraceuticals in Chemoresistance to Cancer. Elsevier; 2018. pp. 61-76. [DOI: 10.1016/b978-0-12-812373-7.00003-6] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
27 Yang M, Li Y, Shen X, Ruan Y, Lu Y, Jin X, Song P, Guo Y, Zhang X, Qu H, Shao Y, Quan C. CLDN6 promotes chemoresistance through GSTP1 in human breast cancer. J Exp Clin Cancer Res 2017;36:157. [PMID: 29116019 DOI: 10.1186/s13046-017-0627-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
28 Wu T, Chen L, Bu L, Gao J, Zhang W, Jia J. CD44 + cancer cell-induced metastasis: A feasible neck metastasis model. European Journal of Pharmaceutical Sciences 2017;101:243-50. [DOI: 10.1016/j.ejps.2017.02.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
29 Sun Y, Qiao Y, Liu Y, Zhou J, Wang X, Zheng H, Xu Z, Zhang J, Zhou Y, Qian L, Zhang C, Lou H. ent-Kaurane diterpenoids induce apoptosis and ferroptosis through targeting redox resetting to overcome cisplatin resistance. Redox Biol 2021;43:101977. [PMID: 33905957 DOI: 10.1016/j.redox.2021.101977] [Reference Citation Analysis]
30 Fayez S, Feineis D, Mudogo V, Seo E, Efferth T, Bringmann G. Ancistrolikokine I and further 5,8′-coupled naphthylisoquinoline alkaloids from the Congolese liana Ancistrocladus likoko and their cytotoxic activities against drug-sensitive and multidrug resistant human leukemia cells. Fitoterapia 2018;129:114-25. [DOI: 10.1016/j.fitote.2018.06.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
31 Jiang M, Zhang E, Liang Z, Zhao Y, Zhang S, Xu H, Wang H, Shu X, Kang X, Sun L, Zhen Y. Liposome-based co-delivery of 7-O-geranyl-quercetin and IGF-1R siRNA for the synergistic treatment of non-small cell lung cancer. Journal of Drug Delivery Science and Technology 2019;54:101316. [DOI: 10.1016/j.jddst.2019.101316] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
32 Sun Z, Qiu Z, Ma B, Wang Z. Encorafenib enhances TRAIL-induced apoptosis of colorectal cancer cells dependent on p53/PUMA signaling. Cytotechnology 2021;73:63-70. [PMID: 33505114 DOI: 10.1007/s10616-020-00442-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Titov AA, Niso M, Candia MD, Kobzev MS, Varlamov AV, Borisova TN, Voskressensky LG, Colabufo NA, Cellamare S, Pisani L, Altomare CD. 3-benzazecine-based cyclic allene derivatives as highly potent P-glycoprotein inhibitors overcoming doxorubicin multidrug resistance. Future Medicinal Chemistry 2019;11:2095-106. [DOI: 10.4155/fmc-2019-0037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
34 Meng T, Qiu G, Hong Y, Yuan M, Lu B, Wu J, Yuan H, Hu F. Effect of chitosan based glycolipid-like nanocarrier in prevention of developing acquired drug resistance in tri-cycle treatment of breast cancer. International Journal of Pharmaceutics 2019;555:303-13. [DOI: 10.1016/j.ijpharm.2018.11.056] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
35 Guo Q, Li X, Cui MN, Sun JL, Ji HY, Ni BB, Yan MX. CD13: A Key Player in Multidrug Resistance in Cancer Chemotherapy. Oncol Res 2020;28:533-40. [PMID: 32532363 DOI: 10.3727/096504020X15919605976853] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
36 Quan YH, Lim J, Choi BH, Choi Y, Choi YH, Park J, Kim HK. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells. Cancer Chemother Pharmacol 2019;83:399-410. [DOI: 10.1007/s00280-018-3737-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
37 Mao C, Zhao Y, Li F, Li Z, Tian S, Debinski W, Ming X. P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors. J Control Release 2018;286:289-300. [PMID: 30081143 DOI: 10.1016/j.jconrel.2018.08.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
38 Zhu Y, Hu Q, Li H. Isoprenylcysteine carboxylmethyltransferase is associated with nasopharyngeal carcinoma chemoresistance and Ras activation. Biochem Biophys Res Commun 2019;516:784-9. [PMID: 31253403 DOI: 10.1016/j.bbrc.2019.06.074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
39 Ramos A, Sadeghi S, Tabatabaeian H. Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them. Int J Mol Sci 2021;22:9451. [PMID: 34502361 DOI: 10.3390/ijms22179451] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Cui Q, Wang J, Assaraf YG, Ren L, Gupta P, Wei L, Ashby CR, Yang D, Chen Z. Modulating ROS to overcome multidrug resistance in cancer. Drug Resistance Updates 2018;41:1-25. [DOI: 10.1016/j.drup.2018.11.001] [Cited by in Crossref: 155] [Cited by in F6Publishing: 154] [Article Influence: 38.8] [Reference Citation Analysis]
41 Wang J, Seebacher N, Shi H, Kan Q, Duan Z. Novel strategies to prevent the development of multidrug resistance (MDR) in cancer. Oncotarget 2017;8:84559-71. [PMID: 29137448 DOI: 10.18632/oncotarget.19187] [Cited by in Crossref: 75] [Cited by in F6Publishing: 72] [Article Influence: 15.0] [Reference Citation Analysis]
42 Najjary S, Mohammadzadeh R, Mansoori B, Vahidian F, Mohammadi A, Doustvandi MA, Khaze V, Hajiasgharzadeh K, Baradaran B. Combination therapy with miR-34a and doxorubicin synergistically induced apoptosis in T-cell acute lymphoblastic leukemia cell line. Med Oncol 2021;38:142. [PMID: 34655330 DOI: 10.1007/s12032-021-01578-8] [Reference Citation Analysis]
43 Guffanti F, Fruscio R, Rulli E, Damia G. The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer. Sci Rep 2016;6:38142. [PMID: 27905519 DOI: 10.1038/srep38142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
44 Aberuyi N, Rahgozar S, Pourabutaleb E, Ghaedi K. Selective dysregulation of ABC transporters in methotrexate-resistant leukemia T-cells can confer cross-resistance to cytarabine, vincristine and dexamethasone, but not doxorubicin. Curr Res Transl Med 2021;69:103269. [PMID: 33071214 DOI: 10.1016/j.retram.2020.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Gao Q, Li XX, Xu YM, Zhang JZ, Rong SD, Qin YQ, Fang J. IRE1α-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells. Cancer Lett 2020;476:67-74. [PMID: 32061752 DOI: 10.1016/j.canlet.2020.02.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
46 Gu X, Jiang Y, Qu Y, Chen J, Feng D, Li C, Yin X. Synthesis and biological evaluation of bifendate derivatives bearing 6,7-dihydro-dibenzo[ c,e ]azepine scaffold as potential P-glycoprotein and tumor metastasis inhibitors. European Journal of Medicinal Chemistry 2018;145:379-88. [DOI: 10.1016/j.ejmech.2018.01.019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
47 Dvorak P, Hlavac V, Mohelnikova-Duchonova B, Liska V, Pesta M, Soucek P. Downregulation of ABC Transporters in Non-neoplastic Tissues Confers Better Prognosis for Pancreatic and Colorectal Cancer Patients. J Cancer. 2017;8:1959-1971. [PMID: 28819395 DOI: 10.7150/jca.19364] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
48 Xu M, Tao Z, Wang S, Jiang Y, Qu M. Suppression of oncogenic protein translation via targeting eukaryotic translation initiation factor 4E overcomes chemo-resistance in nasopharyngeal carcinoma. Biochem Biophys Res Commun 2019;512:902-7. [PMID: 30929914 DOI: 10.1016/j.bbrc.2019.03.118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
49 Czarnomysy R, Surażyński A, Muszynska A, Gornowicz A, Bielawska A, Bielawski K. A novel series of pyrazole-platinum(II) complexes as potential anti-cancer agents that induce cell cycle arrest and apoptosis in breast cancer cells. J Enzyme Inhib Med Chem 2018;33:1006-23. [PMID: 29862867 DOI: 10.1080/14756366.2018.1471687] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
50 Wang HF, Xiang W, Xue BZ, Wang YH, Yi DY, Jiang XB, Zhao HY, Fu P. Cell fusion in cancer hallmarks: Current research status and future indications. Oncol Lett 2021;22:530. [PMID: 34055095 DOI: 10.3892/ol.2021.12791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Khordadmehr M, Shahbazi R, Ezzati H, Jigari-Asl F, Sadreddini S, Baradaran B. Key microRNAs in the biology of breast cancer; emerging evidence in the last decade. J Cell Physiol 2019;234:8316-26. [PMID: 30422324 DOI: 10.1002/jcp.27716] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
52 Liu B, Qi X, Zhang X, Gao D, Fang K, Guo Z, Li L. Med19 is involved in chemoresistance by mediating autophagy through HMGB1 in breast cancer. J Cell Biochem 2019;120:507-18. [DOI: 10.1002/jcb.27406] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
53 Xue D, Han J, Liu Y, Tuo H, Peng Y. Current perspectives on exosomes in the diagnosis and treatment of hepatocellular carcinoma (review). Cancer Biol Ther 2021;22:279-90. [PMID: 33847207 DOI: 10.1080/15384047.2021.1898728] [Reference Citation Analysis]
54 Li Z, Xu D, Tong X, Shan C. Inhibition of β-glucosidase overcomes gastric cancer chemoresistance through inducing lysosomal dysfunction. Clin Res Hepatol Gastroenterol 2021;45:101456. [PMID: 32507687 DOI: 10.1016/j.clinre.2020.04.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Petanidis S, Kioseoglou E, Salifoglou A. Metallodrugs in Targeted Cancer Therapeutics: Aiming at Chemoresistance- related Patterns and Immunosuppressive Tumor Networks. CMC 2019;26:607-23. [DOI: 10.2174/0929867324666171116125908] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
56 Wei R, Cao G, Deng Z, Su J, Cai L. miR-140-5p attenuates chemotherapeutic drug-induced cell death by regulating autophagy through inositol 1,4,5-trisphosphate kinase 2 (IP3k2) in human osteosarcoma cells. Biosci Rep 2016;36:e00392. [PMID: 27582507 DOI: 10.1042/BSR20160238] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 5.7] [Reference Citation Analysis]
57 Aljuhani E, Aljohani MM, Alsoliemy A, Shah R, Abumelha HM, Saad FA, Hossan A, Al-Ahmed ZA, Alharbi A, El-Metwaly NM. Synthesis and characterization of Cu(II)-pyrazole complexes for possible anticancer agents; conformational studies as well as compatible in-silico and in-vitro assays. Heliyon 2021;7:e08485. [PMID: 34901511 DOI: 10.1016/j.heliyon.2021.e08485] [Reference Citation Analysis]
58 Oblad R, Doughty H, Lawson J, Christensen M, Kenealey J. Application of Mixture Design Response Surface Methodology for Combination Chemotherapy in PC-3 Human Prostate Cancer Cells. Mol Pharmacol 2018;94:907-16. [DOI: 10.1124/mol.117.111450] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
59 Yan H, Du X, Wang R, Zhai G. Progress in the study of D-α-tocopherol polyethylene glycol 1000 succinate (TPGS) reversing multidrug resistance. Colloids Surf B Biointerfaces 2021;205:111914. [PMID: 34130211 DOI: 10.1016/j.colsurfb.2021.111914] [Reference Citation Analysis]
60 Wang X, Qiao D, Chen L, Xu M, Chen S, Huang L, Wang F, Chen Z, Cai J, Fu L. Chemotherapeutic drugs stimulate the release and recycling of extracellular vesicles to assist cancer cells in developing an urgent chemoresistance. Mol Cancer 2019;18:182. [PMID: 31830995 DOI: 10.1186/s12943-019-1114-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
61 Zhang Y, Zhang Q, Wei F, Liu N. Progressive study of effects of erianin on anticancer activity. Onco Targets Ther 2019;12:5457-65. [PMID: 31371985 DOI: 10.2147/OTT.S200161] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
62 Kalinina EV, Chernov NN. Why does chemotherapy stop affecting the cells of ovarian and breast tumors? Future Oncology 2018;14:1137-40. [DOI: 10.2217/fon-2018-0001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
63 Wang W, Liang Z, Ma P, Zhao Q, Dai M, Zhu J, Han X, Xu H, Chang Q, Zhen Y. Application of CRISPR/Cas9 System to Reverse ABC-Mediated Multidrug Resistance. Bioconjug Chem 2021;32:73-81. [PMID: 33393280 DOI: 10.1021/acs.bioconjchem.0c00627] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 Chen R, Wang G, Zheng Y, Hua Y, Cai Z. Drug resistance-related microRNAs in osteosarcoma: Translating basic evidence into therapeutic strategies. J Cell Mol Med 2019;23:2280-92. [PMID: 30724027 DOI: 10.1111/jcmm.14064] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
65 Rochman ND, Wolf YI, Koonin EV. Deep phylogeny of cancer drivers and compensatory mutations. Commun Biol 2020;3:551. [PMID: 33009502 DOI: 10.1038/s42003-020-01276-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
66 Wang Q, Cao T, Guo K, Zhou Y, Liu H, Pan Y, Hou Q, Nie Y, Fan D, Lu Y, Zhao X. Regulation of Integrin Subunit Alpha 2 by miR-135b-5p Modulates Chemoresistance in Gastric Cancer. Front Oncol 2020;10:308. [PMID: 32232000 DOI: 10.3389/fonc.2020.00308] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
67 Zhang Z, Qiu N, Yin J, Zhang J, Liu H, Guo W, Liu M, Liu T, Chen D, Luo K, Li H, He Z, Liu J, Zheng G. SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression. Theranostics 2020;10:4290-307. [PMID: 32292495 DOI: 10.7150/thno.41008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
68 Clerc P, Jeanjean P, Hallali N, Gougeon M, Pipy B, Carrey J, Fourmy D, Gigoux V. Targeted Magnetic Intra-Lysosomal Hyperthermia produces lysosomal reactive oxygen species and causes Caspase-1 dependent cell death. Journal of Controlled Release 2018;270:120-34. [DOI: 10.1016/j.jconrel.2017.11.050] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 9.8] [Reference Citation Analysis]
69 Wu M, Zhao Y, Peng N, Tao Z, Chen B. Identification of chemoresistance-associated microRNAs and hub genes in breast cancer using bioinformatics analysis. Invest New Drugs 2021;39:705-12. [PMID: 33394259 DOI: 10.1007/s10637-020-01059-1] [Reference Citation Analysis]
70 Liu P, Wang S, Liu X, Ding J, Zhou W. Platinated graphene oxide: A nanoplatform for efficient gene-chemo combination cancer therapy. Eur J Pharm Sci 2018;121:319-29. [PMID: 29906508 DOI: 10.1016/j.ejps.2018.06.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
71 Qiu J, Chen W, Jiang Y, Chen J, Zhang Y, Gu X. Assessment of a bifendate derivative bearing a 6,7-dihydro-dibenzo[c,e]azepine scaffold as a potential anti-metastatic agent. Medchemcomm 2018;9:1826-30. [PMID: 30542532 DOI: 10.1039/c8md00294k] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
72 Kwantwi LB, Wang S, Sheng Y, Wu Q. Multifaceted roles of CCL20 (C-C motif chemokine ligand 20): mechanisms and communication networks in breast cancer progression. Bioengineered 2021;12:6923-34. [PMID: 34569432 DOI: 10.1080/21655979.2021.1974765] [Reference Citation Analysis]
73 Nevskaya AA, Matveeva MD, Borisova TN, Niso M, Colabufo NA, Boccarelli A, Purgatorio R, de Candia M, Cellamare S, Voskressensky LG, Altomare CD. A New Class of 1-Aryl-5,6-dihydropyrrolo[2,1-a]isoquinoline Derivatives as Reversers of P-Glycoprotein-Mediated Multidrug Resistance in Tumor Cells. ChemMedChem 2018;13:1588-96. [PMID: 29802687 DOI: 10.1002/cmdc.201800177] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
74 Birkeland AC, Swiecicki PL, Brenner JC, Shuman AG. A review of drugs in development for the personalized treatment of head and neck squamous cell carcinoma. Expert Rev Precis Med Drug Dev 2016;1:379-85. [PMID: 28251187 DOI: 10.1080/23808993.2016.1208050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
75 Aali M, Mesgarzadeh AH, Najjary S, Abdolahi HM, Kojabad AB, Baradaran B. Evaluating the role of microRNAs alterations in oral squamous cell carcinoma. Gene 2020;757:144936. [PMID: 32640301 DOI: 10.1016/j.gene.2020.144936] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
76 Molinaro C, Martoriati A, Pelinski L, Cailliau K. Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II. Cancers (Basel) 2020;12:E2863. [PMID: 33027952 DOI: 10.3390/cancers12102863] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
77 Podolski-renić A, Bősze S, Dinić J, Kocsis L, Hudecz F, Csámpai A, Pešić M. Ferrocene–cinchona hybrids with triazolyl-chalcone linkers act as pro-oxidants and sensitize human cancer cell lines to paclitaxel. Metallomics 2017;9:1132-41. [DOI: 10.1039/c7mt00183e] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 3.2] [Reference Citation Analysis]
78 Khordadmehr M, Jigari-Asl F, Ezzati H, Shahbazi R, Sadreddini S, Safaei S, Baradaran B. A comprehensive review on miR-451: A promising cancer biomarker with therapeutic potential. J Cell Physiol 2019;234:21716-31. [PMID: 31140618 DOI: 10.1002/jcp.28888] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
79 Hernandez-Unzueta I, Benedicto A, Olaso E, Sanz E, Viera C, Arteta B, Márquez J. Ocoxin oral solution® as a complement to irinotecan chemotherapy in the metastatic progression of colorectal cancer to the liver. Oncol Lett 2017;13:4002-12. [PMID: 28599406 DOI: 10.3892/ol.2017.6016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
80 Sanomachi T, Suzuki S, Togashi K, Sugai A, Seino S, Okada M, Yoshioka T, Kitanaka C, Yamamoto M. Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs. Cancers (Basel) 2019;11:E1550. [PMID: 31614999 DOI: 10.3390/cancers11101550] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
81 Wei X, Nian J, Zheng J, He Y, Zeng M. Inhibition of cyclin-dependent kinases by AT7519 enhances nasopharyngeal carcinoma cell response to chemotherapy. Cancer Chemother Pharmacol 2020;85:949-57. [PMID: 32279103 DOI: 10.1007/s00280-020-04068-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
82 Jena BC, Das CK, Bharadwaj D, Mandal M. Cancer associated fibroblast mediated chemoresistance: A paradigm shift in understanding the mechanism of tumor progression. Biochim Biophys Acta Rev Cancer 2020;1874:188416. [PMID: 32822826 DOI: 10.1016/j.bbcan.2020.188416] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
83 Jegal ME, Jung SY, Han YS, Kim YJ. C-terminal truncated HBx reduces doxorubicin cytotoxicity via ABCB1 upregulation in Huh-7 hepatocellular carcinoma cells. BMB Rep 2019;52:330-5. [PMID: 30982500 [PMID: 30982500 DOI: 10.5483/bmbrep.2019.52.5.312] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
84 Dembic Z. Antitumor Drugs and Their Targets. Molecules 2020;25:E5776. [PMID: 33297561 DOI: 10.3390/molecules25235776] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
85 Li R, Dong C, Jiang K, Sun R, Zhou Y, Yin Z, Lv J, Zhang J, Wang Q, Wang L. Rab27B enhances drug resistance in hepatocellular carcinoma by promoting exosome-mediated drug efflux. Carcinogenesis 2020;41:1583-91. [PMID: 32390047 DOI: 10.1093/carcin/bgaa029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Pulukuri AJ, Burt AJ, Opp LK, McDowell CM, Davaritouchaee M, Nielsen AE, Mancini RJ. Acquired Drug Resistance Enhances Imidazoquinoline Efflux by P-Glycoprotein. Pharmaceuticals (Basel) 2021;14:1292. [PMID: 34959691 DOI: 10.3390/ph14121292] [Reference Citation Analysis]
87 Xi C, Wang L, Yu J, Ye H, Cao L, Gong Z. Inhibition of eukaryotic translation initiation factor 4E is effective against chemo-resistance in colon and cervical cancer. Biochem Biophys Res Commun 2018;503:2286-92. [PMID: 29959920 DOI: 10.1016/j.bbrc.2018.06.150] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
88 Podolski-renić A, Banković J, Dinić J, Ríos-luci C, Fernandes MX, Ortega N, Kovačević-grujičić N, Martín VS, Padrón JM, Pešić M. DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells. European Journal of Pharmaceutical Sciences 2017;105:159-68. [DOI: 10.1016/j.ejps.2017.05.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
89 Zhao MY, Chen HY, Liu Y, Wang K, Zhang XD, Zhang YF. MiR-29 modulates multidrug resistance of gastric cancer cells by targeting Mcl-1. Shijie Huaren Xiaohua Zazhi 2016; 24(36): 4781-4787 [DOI: 10.11569/wcjd.v24.i36.4781] [Cited by in F6Publishing: 1] [Reference Citation Analysis]